CombiMatrix's miscarriage analysis test now offered

CombiMatrix Corporation, a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, recently announced that ReproSource, Inc., is now offering CombiMatrix's chromosomal microarray analysis (CMA) testing for miscarriage analysis. ReproSource is a clinical reference laboratory providing specialized diagnostic services for unexplained infertility, recurrent pregnancy loss, and premature ovarian failure.

Miscarriage analysis testing, also called Products of Conception testing, is a subset of the overall prenatal testing market. It allows OB/GYN physicians, reproductive endocrinologists, fertility doctors, and clinicians to better determine if there is a genetic cause for a miscarriage or other related event.

Historically, unclear results from genetic testing of products of conception has been frequent, which makes diagnosing the cause of miscarriage difficult and frustrating for both clinicians and patients,” says Benjamin Leader, MD, PhD, the Director of Clinical Research at ReproSource. “The type of genetic testing provided by CombiMatrix significantly increases the frequency with which we can provide reliable answers to our physicians and their patients.”

Mark McDonough, CEO of CombiMatrix, adds, “ReproSource has an outstanding reputation in the fertility testing industry, and we view this partnership as a noteworthy validation of the quality of our tests and the ancillary counseling services we provide in this important new market for us.”